Supplementary Table S1. Clinical characteristics of nodal peripheral T-cell lymphoma according to TBX21 and GATA3 subtype classifications

	PTCL				Non-AITL			
	TBX21 (n=44)	GATA3 (n=17)	Unclassified (n=13)	p-value	TBX21 (n=11)	GATA3 (n=10)	Unclassified (n=6)	p-value
Sex								
Female	18 (40.9)	4 (23.5)	7 (53.8)	.226	6 (54.5)	1 (10.0)	4 (66.7)	.04
Male	26 (59.1)	13 (76.5)	6 (46.2)		5 (45.5)	9 (90.0)	2 (33.3)	
Age (yr)								
≤60	19 (43.2)	8 (47.1)	4 (30.8)	.645	3 (27.3)	4 (40.0)	3 (50.0)	.631
>60	25 (56.8)	9 (52.9)	9 (69.2)		8 (72.7)	6 (60.0)	3 (50.0)	
Ann Arbor stage								
1-2	5 (11.4)	1 (5.9)	3 (23.1)	.349	2 (18.2)	1 (10.0)	3 (50.0)	.161
3-4	39 (88.6)	16 (94.1)	10 (76.9)		9 (81.8)	9 (90.0)	3 (50.0)	
IPI score								
0-2	17 (38.6)	7 (41.2)	5 (38.5)	.982	4 (36.4)	3 (30.0)	3 (50.0)	.724
3-5	27 (61.4)	10 (58.8)	8 (61.5)		7 (63.6)	7 (70.0)	3 (50.0)	
Extranodal site								
≤1	30 (68.2)	11 (68.8)	11 (84.6)	.501	6 (54.5)	6 (60.0)	5 (83.3)	.487
>1	14 (31.8)	5 (31.3)	2 (15.4)		5 (45.5)	4 (40.0)	1 (16.7)	
Serum LDH								
Normal	12 (27.9)	4 (23.5)	1 (8.3)	.369	4 (36.4)	3 (30.0)	1 (16.7)	.696
Elevated	31 (72.1)	13 (76.5)	11 (91.7)		7 (63.6)	7 (70.0)	5 (83.3)	
ECOG PS								
<2	28 (82.4)	11 (78.6)	4 (57.1)	.339	7 (87.5)	5 (62.5)	2 (100)	.352
≥2	6 (17.6)	3 (21.4)	3 (42.9)		1 (12.5)	3 (37.5)	0	
B symptoms								
Absent	26 (61.9)	10 (62.5)	6 (46.2)	.573	10 (90.9)	7 (77.8)	3 (50.0)	.16
Present	16 (38.1)	6 (37.5)	7 (53.8)		1 (9.1)	2 (22.2)	3 (50.0)	
BM involvement								

Absent	17 (38.6)	9 (52.9)	5 (45.5)	.59	4 (36.4)	5 (50.0)	4 (80.0)	.27
Present	27 (61.4)	8 (47.1)	6 (54.5)		7 (63.6)	5 (50.0)	1 (20.0)	

TBX21, T-box transcription factor 21; GATA3, GATA binding protein 3; PTCL, nodal peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase.